ROCHE-NV15801



A phase III, randomized, multicenter, efficacy and safety study comparing the combination of PEG-IFN alfa-2a (Ro 25-8310) and ribavirin to IFN alfa-2b and ribavirin in the treatment of patients with chronic hepatitis C
peg-interferon alpha-2a
NV15801
chronic hepatitis c
Phase 3
 
January 2014